Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study.
Authors
Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, Gherardi G, Xiao J, Dingman R, Xu C, Avetisova E, Dubost-Brama A, Shabbir A
Abstract
Moderate to severe atopic dermatitis (AD) is a chronic inflammatory skin disease that often requires continuous long-term systemic management. Long-term safety and efficacy data for treatment options are critically important.
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the IASP Privacy Policy. By closing this banner, you agree to the use of cookies.Agree
